- Investor's Business Daily•14 hours ago
Barclays analyst Geoff Meacham on Thursday said he expected Gilead Sciences' 2017 outlook to be hindered on limited hepatitis C sales.
- Investor's Business Daily•19 hours ago
Not quite time for champagne yet, but this growth fund is enjoying an uptick in performance.
- Investopedia•3 days ago
It was announced after the close on Friday, the FDA was delaying the approval of Eli Lilly's arthritis drug.
INCY : Summary for Incyte Corporation - Yahoo Finance
Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||86.00 x 100|
|Day's Range||113.00 - 117.62|
|52 Week Range||55.00 - 121.18|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||319.38|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|